Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPTION 2: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis; With an Extension Phase Evaluation of Immediate Release MS1819 Capsules

Next Previous
Trial Profile

OPTION 2: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis; With an Extension Phase Evaluation of Immediate Release MS1819 Capsules

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adrulipase alfa (Primary) ; Adrulipase alfa (Primary)
  • Indications Exocrine pancreatic insufficiency
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OPTION 2
  • Sponsors AzurRx BioPharma; Entero Therapeutics; First Wave Bio

Most Recent Events

  • 16 May 2024 According to a Entero Therapeutics media release, the First Wave BioPharma Changed its name to Entero Therapeutics.
  • 12 Aug 2021 Status changed from active, no longer recruiting to completed.
  • 31 Mar 2021 According to an AzurRx BioPharma media release, the company will host a conference call and live audio webcast to discuss the topline results from this tria.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top